Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by retiredcopon Aug 06, 2021 3:31pm
192 Views
Post# 33664593

Dr Cashman was onto the problem decade ago

Dr Cashman was onto the problem decade ago  EDMONTON (CityNews) Researchers at the University of Alberta may have found a new piece of the puzzle to fully understand COVID-19 — how a protein may be deregulating the immune system and leading to serious long-term conditions or death.

The new study shows COVID-19 patients have high levels of a protein called galectin-9 in their blood plasma. Researchers have also found a link between those elevated levels of galectin-9 and the occurrence of “cytokine storms” within the patient’s body.

A cytokine storm is when cytokine is produced very quickly and released in large quantity, which causes severe inflammation, damages organs and tissue and can lead to death.

 
 
<< Previous
Bullboard Posts
Next >>